Journal of Clinical & Experimental OncologyISSN: 2324-9110

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Vav1 and mutant k-Ras synergize in pancreatic ductal adenocarcinoma development: Lessons from mouse models


Shulamit Katzav

Professor of Cancer Studies, Israel

: J Clin Exp Oncol

Abstract


Pancreatic Ductal AdenoCarcinoma (PDAC), the predominant form of pancreatic cancer, develops via Acinar-Ductal Metaplasia (ADM) and neoplastic precursor lesions, such as Pancreatic Intraepithelial Neoplasia (PanIN). Mutant K-Ras is present in >90% of PDAC and represents the most frequent and the earliest genetic alteration found in low-grade PanIN1A lesions. Identification of additional molecular lesions that affect PDAC is of cardinal importance. One such potential protein is Vav1, a hematopoietic specific signal transducer. Overexpression of Vav1 is implicated in human PDAC and is indicative of a worse survival rate. We generated transgenic mice that express Vav1, K-RasG12D, or both Vav1 and K-RasG12D (K-RasG12D, Vav1) in the pancreas. The number of lesions in the pancreata of K-RasG12D, Vav1 mice exceeded at least three times the number obtained in K-RasG12 mice already at three months post transgene induction. Also, the number of Ki-67 (indicative of proliferation) positive cells in K-RasG12D, Vav1 mice was significantly higher than in Vav1 or K-RasG12D transgenic mice. Thus, expression of Vav1 together with K-RasG12D in the pancreas has a dramatic synergistic effect enhancing ADM formation. Also, continuous Vav1 expression is needed for maintenance of the ADM lesions formed. Interestingly, a dramatic increase in phosphorylation of EGFR and activation of Rac1 was noted in pancreatic malignant lesions of K-RasG12D, Vav1 mice compared to the pancreas of the control transgenic mice. These results suggest that Vav1 regulates a cross-talk between tumor cells and the microenvironment resulting in up-regulation of signal transduction pathways. Identification of Vav1 as a protein that synergizes with mutant K-Ras in PDAC development might pave the way to choosing good candidates for therapeutic drug design.

Biography


Track Your Manuscript

Media Partners

GET THE APP